Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
about
A computational modelling approach combined with cellular electrophysiology data provides insights into the therapeutic benefit of targeting the late Na+ current.Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical SignificanceA computational model predicts adjunctive pharmacotherapy for cardiac safety via selective inhibition of the late cardiac Na current.hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.Drug-induced long QT syndromeA new ECG biomarker for drug toxicity: a combined signal processing and computational modeling study.A phenotypic in vitro model for the main determinants of human whole heart function.The electro-mechanical window in anaesthetized guinea pigs: a new marker in screening for Torsade de Pointes risk.Relevance of anaesthesia for dofetilide-induced torsades de pointes in alpha1-adrenoceptor-stimulated rabbits.Comparison of electrophysiological effects of calcium channel blockers on cardiac repolarization.Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program.Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.The hERG potassium channel as a therapeutic target.Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model.New cell models and assays in cardiac safety profiling.On the relationship among QT interval, atrial fibrillation, and torsade de pointes.QT variability during initial exposure to sotalol: experience based on a large electronic medical record.In silico assessment of drug safety in human heart applied to late sodium current blockersArrhythmic risk biomarkers for the assessment of drug cardiotoxicity: from experiments to computer simulations.Drug safety evaluation of ziprasidone.Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell-derived cardiomyocytes.Drug-induced long QT syndrome and fatal arrhythmias in the intensive care unit.No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder.Automated electrophysiology makes the pace for cardiac ion channel safety screening.Predictive Power of f99 Repolarization Index for the Occurrence of Ventricular Arrhythmias.Slow delayed rectifier K+ current block by HMR 1556 increases dispersion of repolarization and promotes Torsades de Pointes in rabbit ventricles.Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents.Ultrafast sodium channel block by dietary fish oil prevents dofetilide-induced ventricular arrhythmias in rabbit hearts.Have the Findings from Clinical Risk Prediction and Trials Any Key Messages for Safety Pharmacology?Sympathoexcitation increases the QT/RR slope in healthy men: differential effects of hypoxia, dobutamine, and phenylephrine.Automated T-wave analysis can differentiate acquired QT prolongation from congenital long QT syndrome.Predicting torsade de pointes in acquired long QT syndrome: optimal identification of critical QT interval prolongation.
P2860
Q30882091-1A935E16-298E-4719-AEE1-E68C304192AAQ33653994-2269F77F-9299-4468-A8AB-21572CE5A480Q33751744-3CC45E5E-9D23-48FB-9E28-AFE099A387E4Q33845924-976E8800-B839-43BB-AF07-C52153A62B78Q34100661-5E22074D-ABA0-44E9-BADF-239074126E6FQ34358104-AB07C205-B60E-49FB-87D2-C1674F02C7D9Q35096841-802FE5AF-443D-4C3E-B04A-547EE9CE8D2CQ35690281-EB1A8301-8CF4-4A7A-B2EF-D078B8E74A11Q36159213-E203BE92-115D-4B31-B80A-313155B6A264Q36381520-A3E8B76B-C921-4E5D-BBAB-FE83AD30C122Q36488660-3A0C1E3F-08BD-4878-8CB0-E1E2A2B7B338Q36514742-72B802F0-458D-44EF-8D05-02203B0DAF05Q36725206-9618EB52-3124-4307-A739-14663EB9B800Q36734932-DFE4F210-6FBF-48F8-95BB-605F47777095Q36736498-FAD53976-412A-408A-9AEC-A9C2A20FC4BFQ36753583-24263C46-F25F-42BE-9CB7-FA454D663616Q36909315-D6FF3AFD-0B8B-443A-AE08-64381C99A963Q37008418-0BCD6C68-6D7F-4C02-9262-8ACFF19D89CFQ37463278-BDF10FD6-A2F3-4E17-9ECA-71A36F1B1C06Q37706949-F2C0D28A-F94F-4FE5-A5DE-EA46DA41B3A1Q37755876-E0B6A752-6BC8-4F1E-9783-1958C192E499Q37844574-9EAB2965-402F-418C-9194-983E190BF21AQ37960089-F8C15088-82B6-481C-8721-95B1670D5BA6Q38088809-07FAFC74-B1BE-42F5-8ED9-CCAC4ACBFEE2Q38176426-6D9CF62B-225D-4431-BFC5-49651C5C79CAQ39303341-5A336F50-B7E6-4934-8A22-015EB69E0E54Q39331354-00FF1CFE-7AF0-48AF-82DE-98A47D65EEDFQ40278992-E0D44A41-293C-4A9B-80AC-8F4BA63A1E6EQ43223825-CBAC659D-B131-4C61-B5F8-B75162509CABQ43262191-FE334360-058D-45D0-9CF2-8CEF0F56318FQ43463394-FD090520-1E05-40E1-92AD-AD52D95F95CBQ46448157-E2341EE3-BAA7-49FC-9751-5A1F261207BCQ46607609-73AD8983-6F14-426A-970B-EE3C4616E465Q46849151-49693E6A-6350-404C-A950-EDA387891279Q48249778-EB8883DE-5E46-492C-82EF-999485324C53Q49143489-46BBFD33-5307-42DE-A112-2DE5B36BD2D7
P2860
Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Thorough QT/QTc not so thoroug ...... misses profibrillatory drugs.
@ast
Thorough QT/QTc not so thoroug ...... misses profibrillatory drugs.
@en
type
label
Thorough QT/QTc not so thoroug ...... misses profibrillatory drugs.
@ast
Thorough QT/QTc not so thoroug ...... misses profibrillatory drugs.
@en
prefLabel
Thorough QT/QTc not so thoroug ...... misses profibrillatory drugs.
@ast
Thorough QT/QTc not so thoroug ...... misses profibrillatory drugs.
@en
P2860
P1476
Thorough QT/QTc not so thoroug ...... misses profibrillatory drugs.
@en
P2093
Luc M Hondeghem
P2860
P304
P356
10.1111/J.1540-8167.2006.00347.X
P577
2006-03-01T00:00:00Z